Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Current Geriatrics Reports
Erschienen in:

22.07.2017 | Surgical Care for the Geriatric Patient (F Luchette and R Gonzalez, Section Editors)

Prostate Cancer in the Elderly Male: Diagnostic and Management Considerations

verfasst von: Marah C. Hehemann, Kristin G. Baldea, Marcus L. Quek

Erschienen in: Current Geriatrics Reports | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Along with an aging US population comes the growing need for clinical guidelines inclusive of and specific to this unique group. Prostate cancer (PCa) is increasingly recognized as a substantial cause of mortality and morbidity in the elderly. This review seeks to address the unmet need for standardized PCa screening and management protocols for geriatric men and to synthesize recommendations based on recent literature.

Recent Findings

Guidelines regarding PCa screening in elderly men are still being optimized, with many organizations moving toward inclusion of pre-screening global health assessment. Physician compliance with screening and treatment of PCa in geriatric patients is suboptimal, despite advanced age being a predictor of advanced disease. Elderly patients may experience treatment-related side effects which differ from their younger counterparts.

Summary

Providers treating older men are encouraged to utilize comprehensive health assessments which account for comorbidities, functional status, and global well-being, along with shared decision-making, in determining diagnostic and therapeutic pathways.
Literatur
1.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.PubMedCrossRef
2.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.PubMedCrossRef
3.
4.
Elstad EA, Sheridan SL, Lee JG, Rini C, Earp JA, Brewer NT. Have screening harms become newsworthy? News coverage of prostate and colorectal cancer screening since the 2008 USPSTF recommendation changes. J Behav Med. 2014;37(6):1242–51.PubMedCrossRef
5.
6.
Wilt TJ, Dahm P. PSA screening for prostate cancer: why saying no is a high-value health care choice. J Natl Compr Cancer Netw. 2015;13(12):1566–74.CrossRef
7.
Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK. Cancer survival among US whites and minorities: a SEER (surveillance, epidemiology, and end results) program population-based study. Arch Intern Med. 2002;162(17):1985–93.PubMedCrossRef
8.
Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. 2012;157(2):120–34.PubMedCrossRef
9.
AGS Choosing Wisely Workgroup. American geriatrics society identifies another five things that healthcare providers and patients should question. J Am Geriatr Soc. 2014;62(5):950–60.CrossRef
10.
11.
12.
Schaeffer EM, Carter HB, Kettermann A, et al. Prostate specific antigen testing among the elderly—when to stop? J Urol. 2009;181(4):4.CrossRef
13.
14.
Wilson JR, Clarke MG, Ewings P, Graham JD, MacDonagh R. The assessment of patient life-expectancy: how accurate are urologists and oncologists? BJU Int. 2005;95(6):794–8.PubMedCrossRef
15.
Walz J, Gallina A, Perrotte P, et al. Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int. 2007;100(6):1254–8.PubMedCrossRef
16.
Peek ME. Screening mammography in the elderly: a review of the issues. J Am Med Womens Assoc. 2003;58(3):191–8.
17.
Firat S, Bousamra M, Gore E, Byhardt RW. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;52(4):1047–57.PubMedCrossRef
18.
• Walz J, Gallina A, Saad F, et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol. 2007;25(24):3576–81. Manuscript describing a novel nomogram for estimation of 10-year life expectancy in PCa patients undergoing definitive therapy (RP or RT), thereby identifying those patients believed to benefit most from curative treatment. PubMedCrossRef
19.
• NCCN. Practice guidelines in oncology: older adult oncology. 2016. Oncologic practice guidelines specific to geriatric patients published by the NCCN. Includes easy-to-follow flow diagrams detailing approach to decision-making in the older adult and comprehensive geriatric assessment.
20.
Drazer MW, Huo D, Eggener SE. National prostate cancer screening rates after the 2012 US preventive services task force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol. 2015;33(22):2416–23.PubMedCrossRef
21.
Hutchinson R, Akhtar A, Haridas J, Bhat D, Roehrborn C, Lotan Y. Testing and referral patterns in the years surrounding the US preventive services task force recommendation against prostate-specific antigen screening. Cancer. 2016;122(24):3785–93.PubMedCrossRef
22.
Cohn JA, Wang CE, Lakeman JC, et al. Primary care physician PSA screening practices before and after the final U.S. preventive services task force recommendation. Urol Oncol. 2014;32(1):41.e30.CrossRef
23.
Drazer MW, Prasad SM, Huo D, et al. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer. 2014;120(10):1491–8.PubMedCrossRef
24.
Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. preventive services task force. Ann Intern Med. 2011;155(11):762–71.PubMedCrossRef
25.
Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA. 2006;296(19):2336–42.PubMedCrossRef
26.
Sun L, Caire AA, Robertson CN, et al. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol. 2009;182(5):2242–8.PubMedCrossRef
27.
Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer. 2012;118(12):3062–70.PubMedCrossRef
28.
Schwartz KL, Alibhai SM, Tomlinson G, Naglie G, Krahn MD. Continued undertreatment of older men with localized prostate cancer. Urology. 2003;62(5):860–5.PubMedCrossRef
29.
• Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28(7):1117–23. Registry study demonstrating the propensity of older men to undergo less invasive treatment of localized PCa. PubMedPubMedCentralCrossRef
30.
Rice KR, Colombo ML, Wingate J, et al. Low risk prostate cancer in men ≥70 years old: to treat or not to treat. Urol Oncol. 2013;31(6):755–60.PubMedCrossRef
31.
• Droz JP, Aapro M, Balducci L, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the international society of geriatric oncology. Lancet Oncol. 2014;15(9):404. Most recent SIOG consensus statement on PCa describing assessment of life expectancy, comorbidities, and health status. Authors describe G8 rapid geriatric assessment instrument and stratification of treatment options by level of health impairment. CrossRef
32.
Daskivich TJ, Fan KH, Koyama T, et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med. 2013;158(10):709–17.PubMedPubMedCentralCrossRef
33.
Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370(10):932–42.PubMedPubMedCentralCrossRef
34.
Pierorazio PM, Humphreys E, Walsh PC, Partin AW, Han M. Radical prostatectomy in older men: survival outcomes in septuagenarians and octogenarians. BJU Int. 2010;106(6):791–5.PubMedCrossRef
35.
Greco KA, Meeks JJ, Wu S, Nadler RB. Robot-assisted radical prostatectomy in men aged > or =70 years. BJU Int. 2009;104(10):1492–5.PubMedCrossRef
36.
Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol. 2004;172(6 Pt 1):2227–31.PubMedCrossRef
37.
Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT. Factors predicting recovery of erections after radical prostatectomy. J Urol. 2000;164(6):1929–34.PubMedCrossRef
38.
Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. N Engl J Med. 2002;346(15):1138–44.PubMedCrossRef
39.
Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the prostate cancer outcomes study. JAMA. 2000;283(3):354–60.PubMedCrossRef
40.
• Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250–61. Prospective study demonstrating advanced age as a risk factor for treatment-related sexual, urinary, and bowel sequelae and impact of these effects on patient quality of life and partner satisfaction. PubMedCrossRef
41.
Mohamad BA, Marszalek M, Brossner C, et al. Radical prostatectomy in Austria: a nationwide analysis of 16,524 cases. Eur Urol. 2007;51(3):8. discussion 689 CrossRef
42.
• D'Amico AV, Chen MH, Renshaw A, Loffredo M, Kantoff PW. Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2015;314(12):1291–3. Randomized trial demonstrating survival benefit conferred by concomitant short-term ADT with definitive RT versus RT alone in PCa patients with minimal comorbidities. PubMedCrossRef
43.
D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299(3):289–95.PubMed
44.
Hoffman KE, Chen MH, Moran BJ, et al. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer. Cancer. 2010;116(11):2590–5.PubMedCrossRef
45.
Skwarchuk MW, Jackson A, Zelefsky MJ, et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys. 2000;47(1):103–13.PubMedCrossRef
46.
Jani AB, Parikh SD, Vijayakumar S, Gratzle J. Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer. Urology. 2005;65(6):1157–62.PubMedCrossRef
47.
Chen AB, D'Amico AV, Neville BA, Earle CC. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol. 2006;24(33):5298–304.PubMedCrossRef
48.
• Kunkler IH, Audisio R, Belkacemi Y, et al. Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force. Ann Oncol. 2014;25(11):2134–46. Comprehensive review of evidence-based guidelines for RT in geriatric oncology patients, including men with PCa. PubMedCrossRef
49.
Martin NE, D'Amico AV. Progress and controversies: radiation therapy for prostate cancer. CA Cancer J Clin. 2014;64(6):389–407.PubMedCrossRef
50.
Loeb S, Walter D, Curnyn C, Gold HT, Lepor H, Makarov DV. How active is active surveillance? Intensity of followup during active surveillance for prostate cancer in the United States. J Urol. 2016;196(3):721–6.PubMedPubMedCentralCrossRef
51.
Watts S, Leydon G, Eyles C, et al. A quantitative analysis of the prevalence of clinical depression and anxiety in patients with prostate cancer undergoing active surveillance. BMJ Open. 2015;5(5):006674.CrossRef
52.
• Tan HJ, Marks LS, Hoyt MA, et al. The relationship between intolerance of uncertainty and anxiety in men on active surveillance for prostate cancer. J Urol. 2016;195(6):1724–30. Study evaluating the emotional impact of active surveillance on men with PCa. PubMedPubMedCentralCrossRef
53.
Parker PA, Davis JW, Latini DM, et al. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016;117(3):469–77.PubMedCrossRef
Metadaten
Titel
Prostate Cancer in the Elderly Male: Diagnostic and Management Considerations
verfasst von
Marah C. Hehemann
Kristin G. Baldea
Marcus L. Quek
Publikationsdatum
22.07.2017
Verlag
Springer US
Erschienen in
Current Geriatrics Reports / Ausgabe 3/2017
Elektronische ISSN: 2196-7865
DOI
https://doi.org/10.1007/s13670-017-0213-1

Weitere Artikel der Ausgabe 3/2017

Updates in the Evaluation of Older Women with Pelvic Floor Disorders

  • Geriatric Urology (H Richter, Section Editor)

Breast Cancer Care in the Elderly Patient

  • Surgical Care for the Geriatric Patient (F Luchette and R Gonzalez, Section Editors)

Alternative Fixation in Osteoporotic Fractures

  • Geriatric Orthopedics (E Meinberg, Section Editor)

Thoracic Surgery in Older Patients

  • Surgical Care for the Geriatric Patient (F Luchette and R Gonzalez, Section Editors)

Erratum to: Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes

  • Open Access
  • Erratum

Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes

  • Open Access
  • Nutrition, Obesity, and Diabetes (H Florez, Section Editor)

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Verbände und Cremes gegen Dekubitus: „Wir wissen nicht, was sie bringen!“

Die Datenlage zur Wirksamkeit von Verbänden oder topischen Mitteln zur Prävention von Druckgeschwüren sei schlecht, so die Verfasser einer aktuellen Cochrane-Studie. Letztlich bleibe es unsicher, ob solche Maßnahmen den Betroffenen nutzen oder schaden.

Schützt das tägliche Glas Milch vor Darmkrebs?

Die Milch machts – sie bietet Frauen nach Daten einer großen Ernährungsanalyse den besten Darmkrebsschutz aller Lebensmittel, was am hohen Kalziumgehalt liegen dürfte. Am anderen Ende des Spektrums steht der Alkoholkonsum: Das Glas Wein am Abend ist eher ungünstig.

Vorsicht mit Glukokortikoiden bei Glomerulopathie

Auch niedrig dosierte Glukokortikoide zur Behandlung einer primären Glomerulopathie lassen offenbar die Infektionsgefahr steigen. In einer US-Studie hing das Risiko vor allem mit der kombinierten Anwendung von Immunsuppressiva zusammen.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise